Jonathan Zager
Expertise in
18
conditions

Dr. Jonathan Zager

Surgical Oncology | General Surgery
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
12902 Usf Magnolia Dr, 
Tampa, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
18
conditions
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
12902 Usf Magnolia Dr, 
Tampa, FL 

Overview

Jonathan Zager is a Surgical Oncologist and a General Surgeon in Tampa, Florida. Dr. Zager is highly rated in 18 conditions, according to our data. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Adult Soft Tissue Sarcoma, Lymphadenectomy, and Liver Embolization.

His clinical research consists of co-authoring 294 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Surgical Oncology
General Surgery

Licenses

Surgery in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

H LEE MOFFITT CANCER CTR AND RES INST LIFE TIME CANCER SCRN CTR INC
12902 Usf Magnolia Dr, Tampa, FL 33612

Additional Areas of Focus

Dr. Zager has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C/D Melanoma Patients
An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C/D Melanoma Patients
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug, Procedure
Study Drugs: Daromun, Adjuvant Therapy
Study Phase: Phase 3
Phase I Study of Escalating Doses of XL888 With Vemurafenib Plus Cobimetinib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
Phase I Study of Escalating Doses of XL888 With Vemurafenib Plus Cobimetinib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 08, 2025
Intervention Type: Drug
Study Drugs: XL888, Vemurafenib, Cobimetinib
Study Phase: Phase 1
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: Safety and Biomarker Analysis
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: Safety and Biomarker Analysis
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: Cemiplimab
Study Phase: Phase 1
Neoadjuvant Immunotherapy With Intratumoral Tavokinogene Telseplasmid (Tavo) Plus Electroporation in Combination With Intravenous Nivolumab in Patients With Operable Locally- Regionally Advanced Melanoma
Neoadjuvant Immunotherapy With Intratumoral Tavokinogene Telseplasmid (Tavo) Plus Electroporation in Combination With Intravenous Nivolumab in Patients With Operable Locally- Regionally Advanced Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Device, Drug
Study Drugs: Tavo, Nivolumab
Study Phase: Phase 2
A Pilot Clinical Trial Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
A Pilot Clinical Trial Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Nivolumab, CD137, Cyclophosphamide, Fludarabine, Tumor- Infiltrating Lymphocytes Infusion, Interleukin-2
Study Phase: Early Phase 1
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Combination product
Study Drug: Melphalan/Hepatic Device System
Study Phase: Phase 3
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Enrollment Status: Unknown
Publish Date: December 21, 2023
Intervention Type: Combination product
Study Phase: Phase 3
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Enrollment Status: Unknown
Publish Date: November 21, 2023
Intervention Type: Drug
Study Drugs: PV-10, Pembrolizumab
Study Phase: Phase 1/Phase 2
Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study
Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study
Enrollment Status: Withdrawn
Publish Date: June 28, 2023
Intervention Type: Drug
Study Drug: Pramlintide
Study Phase: Early Phase 1
A Phase 1 Study of HDAC Inhibitor Panobinostat (LBH 589) Administered in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
A Phase 1 Study of HDAC Inhibitor Panobinostat (LBH 589) Administered in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Drug
Study Drugs: Panobinostat, Ipilimumab
Study Phase: Phase 1
PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Enrollment Status: Terminated
Publish Date: January 19, 2022
Intervention Type: Drug
Study Phase: Phase 3
An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carcinoma
An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carcinoma
Enrollment Status: Withdrawn
Publish Date: December 18, 2017
Intervention Type: Drug, Device
Study Phase: Phase 2
View 11 Less Clinical Trials

294 Total Publications

ASO Visual Abstract: International Survey on Evidence for Index Lymph Node Surgery Following Neoadjuvant Systemic Therapy for Stage III Melanoma.
ASO Visual Abstract: International Survey on Evidence for Index Lymph Node Surgery Following Neoadjuvant Systemic Therapy for Stage III Melanoma.
Journal: Annals of surgical oncology
Published: January 23, 2026
Similar Doctors
Expertise in
36
conditions
Dr. Ricardo Gonzalez
Surgical Oncology | General Surgery
Expertise in
36
conditions
Dr. Ricardo Gonzalez
Surgical Oncology | General Surgery

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ricardo Gonzalez is a Surgical Oncologist and a General Surgeon in Tampa, Florida. Dr. Gonzalez is highly rated in 36 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Gastrointestinal Stromal Tumor, Nephrectomy, and Reconstructive Urology Surgery.

Pamela J. Hodul
Expertise in
27
conditions
Dr. Pamela J. Hodul
Surgical Oncology | General Surgery
Expertise in
27
conditions
Dr. Pamela J. Hodul
Surgical Oncology | General Surgery

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Pamela Hodul is a Surgical Oncologist and a General Surgeon in Tampa, Florida. Dr. Hodul is highly rated in 27 conditions, according to our data. Her top areas of expertise are Pancreatic Cancer, Ampullary Cancer, Familial Pancreatic Cancer, Pancreatectomy, and Small Bowel Resection. Dr. Hodul is currently accepting new patients.

Mokenge P. Malafa
Expertise in
23
conditions
Dr. Mokenge P. Malafa
General Surgery | Surgical Oncology
Expertise in
23
conditions
Dr. Mokenge P. Malafa
General Surgery | Surgical Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-860-2778
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Mokenge Malafa is a General Surgeon and a Surgical Oncologist in Tampa, Florida. Dr. Malafa is highly rated in 23 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, Pancreatectomy, and Small Bowel Resection. Dr. Malafa is currently accepting new patients.

Frequently Asked Questions about Dr. Jonathan Zager

How do I make an appointment with Dr. Jonathan Zager?

You can book an appointment with Dr. Jonathan Zager by calling their office at 888-860-2778. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jonathan Zager a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jonathan Zager is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jonathan Zager specialize in?

While Dr. Jonathan Zager is a Surgical Oncology, they have specific expertise in Melanoma, Merkel Cell Carcinoma, and Adult Soft Tissue Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Surgical Oncology.

Does Dr. Jonathan Zager participate in research or clinical trials?

Yes. Dr. Jonathan Zager has published 294 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Jonathan Zager's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jonathan Zager accept my insurance?

Dr. Jonathan Zager accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 888-860-2778 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zager's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 8 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile